MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

Company Overview - May Health is a clinical-stage medical device company based in Paris and California, focused on developing treatments for Polycystic Ovary Syndrome (PCOS) [5][6] - The company is currently investigating its proprietary Ovarian Rebalancing™ technology as a treatment for PCOS-related infertility through the REBALANCE clinical study, which is an FDA-approved investigational device exemption (IDE) trial [5][6] Leadership Transition - Colby Holtshouse has been appointed as President and CEO of May Health, bringing extensive experience in women's health and senior leadership from previous roles at Organon, Alydia Health, and Pelvalon [1][2] - The leadership change comes as the company aims to complete the REBALANCE study, which is crucial for obtaining marketing authorization for the Ovarian Rebalancing procedure [2][3] Technology and Clinical Focus - The Ovarian Rebalancing procedure is designed to restore ovulation in women with PCOS who do not respond to oral ovulation induction medications, utilizing a one-time, ultrasound-guided transvaginal ablation procedure [2][4] - The procedure aims for same-day recovery with minimal discomfort, targeting the ablation of excess androgen-producing ovarian tissue to establish regular ovulatory menstrual cycles [2][4] Market Context - PCOS affects approximately 10% of reproductive-aged women and is a leading cause of female infertility, presenting significant health challenges [4] - The condition is associated with various symptoms, including irregular menstruation, acne, and increased risks for Type 2 diabetes and heart disease [4] Financial Background - May Health completed a $25 million Series B funding round in 2024, co-led by Trill Impact and BPI France, following an earlier €10 million Series A round led by Sofinnova Partners [6]